荟萃分析:炎症性肠病患者中非酒精性脂肪性肝病的患病率及危险因素
该荟萃分析检索截至2021年9月30日的文献,纳入44项观察性研究、14947例来自18个国家的成人炎症性肠病(IBD)患者。全球IBD患者非酒精性脂肪性肝病(NAFLD)合并患病率为30.7%(95%CI 26.5-34.9),IBD患者NAFLD风险约为健康对照的1.96倍(OR 1.96,95%CI 1.13-3.41)。
要点
- 全球IBD患者NAFLD合并患病率为30.7%(95%CI 26.5-34.9),存在地区差异。
- IBD患者NAFLD风险约为健康对照的1.96倍(OR 1.96,95%CI 1.13-3.41)。
- 年龄(校正OR 1.03,95%CI 1.01-1.05)和BMI(校正OR 1.27,95%CI 1.22-1.32)与NAFLD风险升高显著相关。
核心结论
- 全球多达三分之一的IBD患者患有NAFLD。
- IBD患者NAFLD风险约为健康受试者的两倍。
研究设计与样本
- 系统检索Embase、PubMed、Web of Science、Scopus和ProQuest,检索时间自建库至2021年9月30日。
- 纳入报告≥50例成人IBD患者NAFLD患病率的观察性研究,最终纳入44项研究、14947例受试者,来自18个不同国家。
主要发现
- 全球IBD患者NAFLD合并患病率为30.7%(95%CI 26.5-34.9),存在地区差异。
- 克罗恩病(CD)患者与溃疡性结肠炎(UC)患者NAFLD的OR无显著差异(1.16,95%CI 0.93-1.44)。
- IBD患者NAFLD风险约为健康受试者的1.96倍(OR 1.96,95%CI 1.13-3.41)。
- 年龄(校正OR 1.03,95%CI 1.01-1.05)和BMI(校正OR 1.27,95%CI 1.22-1.32)与NAFLD风险升高呈统计学显著关联。
- 基于6项研究,合并NAFLD的IBD患者晚期肝纤维化合并患病率为13.6%(95%CI 7.6-19.7)。
关键数值与推荐
- NAFLD诊断可基于影像学、组织病理学和/或肝脏脂肪变性指数。
- 评估的潜在危险因素包括性别、年龄、BMI、糖尿病、高血压、血脂异常、既往手术(肠切除)、皮质类固醇、生物制剂和免疫调节剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is found in inflammatory bowel disease (IBD). However, uncertainties remain on the magnitude of the association. AIMS: To explore systematically the prevalence of, and risk factors for, NAFLD in IBD patients. METHODS: We searched medical literature using Embase, PubMed, Web of Science, Scopus and ProQuest, from inception to September 30, 2021. We included observational studies reporting the prevalence of NAFLD in ≥50 adult patients with IBD. Diagnosis of NAFLD could be based on imaging, histopathology, and/or hepatic steatosis index. Sex, age, body mass index (BMI), diabetes, hypertension, dyslipidemia, prior surgery (bowel resection), corticosteroids, biologics and immunomodulators were assessed as potential risk factors for NAFLD. RESULTS: Of 1893 citations, 44 eligible studies were finally included, comprising 14 947 subjects from 18 different countries. Pooled prevalence of NAFLD was 30.7% (95% confidence interval [CI] 26.5-34.9) in patients with IBD worldwide, which varied regionally. No significant difference was observed in the odds ratio (OR) of NAFLD among Crohn's disease (CD) patients compared with ulcerative colitis (UC) patients (1.16, 95% CI 0.93-1.44). Risk of NAFLD was almost twice as high in patients with IBD as in healthy subjects (OR 1.96, 95% CI 1.13-3.41). Age (adjusted OR 1.03, 95% CI 1.01-1.05) and BMI (adjusted OR 1.27, 95% CI 1.22-1.32) were statistically significantly associated with increased risk of NAFLD. The pooled prevalence of advanced liver fibrosis in IBD patients with NAFLD was 13.6% (95% CI 7.6-19.7) based on six studies. CONCLUSION: Up to one-third of patients with IBD experienced NAFLD worldwide. The risk of NAFLD was two times higher in IBD patients versus healthy subjects.
引用
- Zamani M, Alizadeh-Tabari S, Singh S, et al. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35274325. doi:10.1111/apt.16879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。